title: Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males.
abstract: BACKGROUND
  We recently identified a novel anorexigenic protein, nesfatin-1, which is processed from nesfatin/nucleobindin-2 (NUCB2). However, the clinical importance of this protein has not been determined.
  
  
  OBJECTIVE
  To investigate its clinical significance in humans, we have established a new specific enzyme-linked immunosorbent assay (ELISA) for human nesfatin-1 in peripheral blood and measured its circulating concentration in healthy subjects.
  
  
  METHODS
  The new sandwich-type ELISA method was validated and then used to measure nesfatin-1 levels in plasma samples, under overnight fasting conditions, followed by oral glucose tolerance and meal tests.
  
  
  METHODS
  A total of 43 nonobese males (age: 24.5 ± 0.6, body mass index (BMI); 21.1 ± 0.3 kg/m(2)) were recruited to the study for evaluating fasting concentrations of nesfatin-1. In those, fifteen subjects underwent a 75- g oral glucose tolerance test (OGTT) and another 15 underwent a meal test. In addition, fasting concentrations of nesfatin-1 were measured in nine males with high BMI (age: 32.4 ± 3.7, BMI; 37.3 ± 3.8 kg/m(2)).
  
  
  RESULTS
  Peripheral concentrations of nesfatin-1 showed a significant negative correlation with BMI, percentage body fat, body fat weight and blood glucose (P < 0.05). Nesfatin-1 concentrations were not significantly changed during OGTT and meal tests. Fasting nesfatin-1 levels were significantly lower in subjects with high BMI compared to nonobese subjects (P < 0.05).
  
  
  CONCLUSIONS
  A new specific and sensitive ELISA for nesfatin-1 was established. Further accumulation of clinical observations is necessary to clarify the role of circulating nesfatin-1 in various metabolic disorders.
authors.affiliation: Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma, Japan Shibayagi Co Ltd, Shibukawa, Gunma, Japan. ttenmon@med.gunma-u.ac.jp
authors.forename: Takafumi
authors.initials: T
authors.lastname: Tsuchiya
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Shimizu
authors.forename: Masanobu
authors.initials: M
authors.lastname: Yamada
authors.forename: Aya
authors.initials: A
authors.lastname: Osaki
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Oh-I
authors.forename: Yasuyo
authors.initials: Y
authors.lastname: Ariyama
authors.forename: Hiroki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Shuichi
authors.initials: S
authors.lastname: Okada
authors.forename: Koshi
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Tetsurou
authors.initials: T
authors.lastname: Satoh
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kojima
authors.forename: Masatomo
authors.initials: M
authors.lastname: Mori
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D002135:Calcium-Binding Proteins; D004268:DNA-Binding Proteins; D004797:Enzyme-Linked Immunosorbent Assay; D005215:Fasting / Q000097:blood*; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D009419:Nerve Tissue Proteins; D000080866:Nucleobindins; D036361:Peptide Hormones / Q000097:blood* / Q000502:physiology
chemical_list: D001786:Blood Glucose; D002135:Calcium-Binding Proteins; D004268:DNA-Binding Proteins; D007328:Insulin; C000630650:NUCB2 protein, human; D009419:Nerve Tissue Proteins; D000080866:Nucleobindins; D036361:Peptide Hormones